Glaukos Launches New Direct Sales Organization and Begins Commercialization of iStent inject® Trabecular Micro-Bypass Stent in Canada
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has created a direct sales organization and initiated the commercial launch of the iStent inject® Trabecular Micro-Bypass Stent in Canada. The iStent inject system is preloaded with two micro-scale stents that the surgeon p
